Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659018 | 0.86 | ALDH1A1 (0.36) | TACR3ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5658113 | 0.83 | DPP4 (0.32) | GAAALDH1A1POLB | |
| SCHEMBL5658745 | 0.78 | — | — | |
| SCHEMBL5659365 | 0.77 | RECQL (0.34) | ALDH1A1KMT2ARECQL | |
| SCHEMBL5659385 | 0.77 | CTSS (0.34) | ALDH1A1MEN1KMT2APOLBRAB9A | |
| SCHEMBL5658076 | 0.76 | — | — | |
| SCHEMBL5658863 | 0.76 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2APOLBRAB9A | |
| SCHEMBL5658025 | 0.75 | MEN1 (0.34) | GAAALDH1A1MGLLMEN1KMT2A | |
| SCHEMBL5656031 | 0.74 | ALDH1A1 (0.41) | TACR3ALDH1A1POLBRAB9A | |
| SCHEMBL5655653 | 0.71 | HRH3 (0.45) | KCNH2HRH3GAALMNALIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192953-B2 | Antibacterial agents | VERNALIS (OXFORD) LIMITED (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | VERNALIS (OXFORD) LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1567504-A1 | ANTIBACTERIAL AGENTS | Vernalis (Oxford) Ltd (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050638-A1 | ANTIBACTERIAL AGENTS | VERNALIS (OXFORD) LTD. (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | HRH2, HCAR3, HCAR2 | KCNH2 617/4885HRH3 5/4885GAA 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.